LIXTE.jpg
The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdingsā€™ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
August 06, 2019 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it signed a clinical trial agreement with the Spanish Sarcoma Group (Grupo...